U.S. pharma big copyright scrapped two experimental weight loss products past 12 months—a at the time-day by day pill, lotiglipron, because of elevated liver enzymes along with a 2 times-day-to-day capsule, danuglipron, due to potent side effects—but CEO Albert Bourla has explained the company is determined to “Participate in and earn” insi